Standard treatment for resectable IIIa/N2 non-small-cell lung cancer (NSCLC) is still under debate. Optional treatments include chemotherapy, radiotherapy and surgery, other options include target therapy and immunotherapy. Multidisciplinary treatment has therefore been emphasized by various clinical trials, including bimodality strategy which has been defined as chemotherapy plus surgery or chemotherapy plus radiotherapy, and trimodality treatment which refers to chemotherapy plus surgery and radiotherapy. However, there is still no consensus on the optimal strategy on treating resectable IIIa/N2 NSCLC. Therefore, we reviewed a series of phase II and III clinical trials as well as some meta-analyses and case reports to compare the efficacy of different strategies on survival of cN2 NSCLC, and concluded that for resectable IIIa/N2 NSCLC surgery is recommended, and that strategy of chemotherapy plus surgery may not achieve better survival than that of chemotherapy plus radiotherapy. Size of tumor as well as lymph nodes should be taken into account when choosing optimal therapy, so that promising individualized strategy could be given to patients with resectable stage IIIa/N2 NSCLC. .
【中文题目：可切除IIIa/N2期非小细胞肺癌治疗模式探讨】 【中文摘要：临床可切除IIIa/N2期非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗模式一直存在争议，化疗、放疗、手术等治疗手段都有可改善其生存的报道，靶向治疗和免疫治疗的研究也有较多新进展，联合治疗的选择更是很多临床试验研究的重点。联合治疗包括化疗联合手术或放疗，以及化疗、放疗和手术三种治疗的联合。对于NSCLC最佳治疗模式目前尚无定论。本文通过对多项II期、III期临床试验及meta分析、个案报道的综述回顾，比较不同治疗方式对临床可切除IIIa/N2期NSCLC的生存影响，结果显示多学科治疗中手术对于延长患者生存是必要的选择，而新辅助化疗后联合手术并不优于联合放疗。依据肿瘤大小、淋巴结累及情况等进行个体化治疗是未来值得进一步探索的方向。 】 【中文关键词：可切除IIIa/N2期非小细胞肺癌；化疗；放疗；手术】.
Keywords: Chemotherapy; Radiotherapy; Resectable IIIa/N2 non-small cell lung cancer; Surgery.